Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adaptive Treatment for Cocaine Dependence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by University of Pennsylvania.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01032135
First received: December 14, 2009
Last updated: August 3, 2011
Last verified: August 2011
  Purpose
  1. Primary objective #1: Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine use over weeks 1-24.

    • Hypothesis 1: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce higher rates of treatment engagement than an intervention focused on engagement in IOP only (e.g., MI-IOP).
    • Hypothesis 2: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce better cocaine use outcomes than an intervention focused on engagement in IOP only (MI-IOP).
    • Secondary analysis 1: Among the Non-engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine use outcomes in each option.
    • Secondary analysis 2: Among the Engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine use outcomes in each option.
  2. Primary objective #2: Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine use outcomes over weeks 1-24.

    • Hypothesis 1: The predicted main effect on retention favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
    • Hypothesis 2: The predicted main effect on cocaine use outcomes favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.

Condition Intervention Phase
Cocaine Dependence
Behavioral: Motivational Interviewing
Behavioral: Telephone counseling
Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adaptive Treatment for Cocaine Dependence

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine use over weeks 1-24. [ Time Frame: engagment measured to week 12, cocaine use measured to week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine use outcomes over weeks 1-24. [ Time Frame: Engagement measured until week 12, cocaine use measured until week 24. ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: October 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1-MI-IOP Engaged
Randomized to treatment as usual, and they attend regularly.
Behavioral: Motivational Interviewing
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Other Name: MI
Experimental: 2-MI-IOP Non-Engaged
Randomized to treatment as usual, and do not attend.
Behavioral: Motivational Interviewing
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Other Name: MI
Behavioral: Telephone counseling
one telephone counseling session per week for 10 weeks.
Other Name: Telephone based stepped care.
Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
One CBT session per week, for 10 weeks.
Other Name: CBT
3-MI-PC Engaged
Randomized to treatment choice, but remain attending treatment as usual.
Behavioral: Motivational Interviewing
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Other Name: MI
Behavioral: Telephone counseling
one telephone counseling session per week for 10 weeks.
Other Name: Telephone based stepped care.
Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
One CBT session per week, for 10 weeks.
Other Name: CBT
Experimental: 4-MI-PC
Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
Behavioral: Motivational Interviewing
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Other Name: MI
Behavioral: Telephone counseling
one telephone counseling session per week for 10 weeks.
Other Name: Telephone based stepped care.
Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
One CBT session per week, for 10 weeks.
Other Name: CBT

Detailed Description:

3. Secondary objective #1: Examine outcomes on three secondary measures: percent days abstinent from all substances, negative consequences of drug use, and HIV high risk behaviors.

  • Hypothesis 1: Outcomes on the secondary measures will be better in MI-PC than in MI-IOP.

    4. Secondary objective #2: Test hypotheses concerning potential mediators of the predicted main effect favoring MI-PC over MI-IOP.

  • Hypothesis 1: The predicted advantage of MI-PC over MI-IOP will be mediated by greater increases in motivation, self-efficacy, commitment to abstinence, and self-help involvement in MI-PC.

    5. Secondary objective #3: Test hypotheses concerning effect of additional MI intervention after initial non-engagement persists through 12 weeks.

  • Hypothesis 1: A second telephone MI intervention will produce higher rates of subsequent engagement and less cocaine use than no further MI.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. meet DSM-IV criteria for lifetime cocaine dependence and have used cocaine in the prior 6 months;
  2. be > 18 years of age;
  3. be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment;
  4. have no regular IV heroin use during the past year;
  5. have access to a telephone;
  6. be willing to be randomized and participate in research; and
  7. no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will
  8. be required to be metropolitan area residents, and
  9. be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.

Exclusion Criteria:

  1. have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment;
  2. have acute medical problem requiring immediate inpatient treatment; or
  3. are currently participating in methadone or other forms of DA treatment, other than IOP.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01032135

Locations
United States, Pennsylvania
NorthEast Treatment Center
Philadelphia, Pennsylvania, United States, 19123
Presbyterian Medical Center
Philadelphia, Pennsylvania, United States, 19104
VAMC
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
  More Information

No publications provided

Responsible Party: James R. McKay, Ph.D., University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01032135     History of Changes
Other Study ID Numbers: 807092, IND: 101,486
Study First Received: December 14, 2009
Last Updated: August 3, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on November 25, 2014